International Clinical Trial: A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)

Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117343) titled 'A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)' on Jan. 22.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Peking University Third Hospital

Condition: Amyotrophic Lateral Sclerosis (ALS)

Recruitment Status: Not Recruiting

Phase: 1-2

Date of First Enrollment: 2026-01-31

Target Sample Size: Test Group:21;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showp...